Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma

Publication date: Available online 25 February 2020Source: Gynecologic Oncology ReportsAuthor(s): Silvia Pelligra, Natalia Buza, Pei Hui, Stefania Bellone, Burak Zeybek, Elena Ratner, Peter E. Schwartz, Giovanni Scambia, Alessandro D. Santin
Source: Gynecologic Oncology Reports - Category: OBGYN Source Type: research

Related Links:

Publication date: Available online 16 March 2020Source: Gynecologic Oncology ReportsAuthor(s): M. Ruhul Quddus, Katrine Hansen, Uma Tantravahi, C. James Sung
Source: Gynecologic Oncology Reports - Category: OBGYN Source Type: research
muel C. Mok Uterine serous carcinoma (USC) is an aggressive variant of endometrial cancer that has not been well characterized. It accounts for less than 10% of all endometrial cancers and 80% of endometrial cancer–related deaths. Currently, staging surgery together with chemotherapy or radiotherapy, especially vaginal cuff brachytherapy, is the main treatment strategy for USC. Whole-exome sequencing combined with preclinical and clinical studies are verifying a series of effective and clinically accessible inhibitors targeting frequently altered genes, such as HER2 and PI3K3CA, in varying USC patient populat...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
In this study, we have analyzed a prospective cohort of 502 early-stage OCs to investigate their frequency, immunohistochemical characteristics, and survival of the 5 main histologic types. Histotype was assigned according to not only the morphologic features but also according to the expression pattern of WT1, p53, Napsin A, and progesterone receptors. In addition, an extended panel including p16, β-catenin, HER2, Arid1A, HINF1B, CK7, CDX2, and CK20 was used to refine the diagnosis in difficult cases. In this series, the frequency of the 5 major histologic types was as follows: endometrioid carcinoma, 32.7%; clear ce...
Source: The American Journal of Surgical Pathology - Category: Pathology Tags: Original Articles Source Type: research
Purpose of review The purpose of this review is to describe the role of the human epidermal growth factor receptor 2 (HER2) as a biomarker and potential target in gynecologic malignancies and to describe contemporary updates in the use of anti-HER2 treatments for these cancers. Recent findings Approximately 25–30% of all patients with uterine serous carcinoma overexpress tumoral HER2. The anti-HER2 antibody trastuzumab represents an effective, targeted therapy with significant efficacy in the treatment of HER2-positive breast and gastric cancer. Recently, trastuzumab efficacy has also been demonstrated in a rand...
Source: Current Opinion in Obstetrics and Gynecology - Category: OBGYN Tags: GYNECOLOGIC CANCER: Edited by Gottfried E. Konecny Source Type: research
Publication date: Available online 8 August 2019Source: Journal of the American Society of CytopathologyAuthor(s): Momin T. Siddiqui, Fernando Schmitt, Andrew ChurgAbstractWe live in the “era” of minimally invasive procedures, molecular testing and personalized care. Effusions have a high sensitivity and often yield diagnostic cytological material. This companion session presented by the American Society of Cytopathology at the 2019 USCAP meeting outlined our current and future projected practices in characterizing, handling and diagnosing serous cavity fluids, and in this second part, the role of theranostics ...
Source: Journal of the American Society of Cytopathology - Category: Cytology Source Type: research
Conclusion MTDH is pro-oncogenic factor playing multifaceted and diverse roles in cancer progression. Its association and central role in regulating signaling pathways such a MAPK, wnt/β-catenin, PI3K/AkT, NF-κβ pathways in various cancers shows that it plays a vital role in metastasis. MTDH contribution to chemo and radiotherapy resistance provides a new direction for the development of anticancer therapeutics. Multiple mechanisms converge to promote expression of MTDH in cancers. Further studies are therefore warranted to determine whether the elevated MTDH expression has prognostic value for development...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Li Liu, Jiajing Lin and Hongying He* Department of Obstetrics and Gynecology, Liuzhou Worker’s Hospital, Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, China Background and Objective: Endometrial cancer (EC) is a common gynecological malignancy worldwide. Despite advances in the development of strategies for treating EC, prognosis of the disease remains unsatisfactory, especially for advanced EC. The aim of this study was to identify novel genes that can be used as potential biomarkers for identifying the prognosis of EC and to construct a novel risk stratification using these genes. Me...
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
Conclusion: Our data suggests that the precancerous unstable CNVs with potentially predisposing genetic backgrounds may foster the onset of driver mutations and the development of independent SM-GGNs during the local stimulation of mutagens. Introduction The widespread use of advanced chest computed tomography (CT) for lung cancer screening has facilitated the detection of ground-glass nodules (GGNs) (1–3). Recent data indicates that up to 20% of GGN patients (3% of the screening population) are diagnosed with synchronous multiple ground-glass nodules (SM-GGNs) (4). GGNs are like atypical adenomatous hyperplasi...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
AbstractMost ovarian carcinomas (OC) are characterized by poor prognosis, particularly the most frequent type high-grade serous carcinoma. Besides PARP inhibitors, target-based therapeutic strategies are not well established. We asked the question which other therapeutic targets could be of potential value and, therefore, analyzed a large cohort of OC for several predictive factors. Two hundred eighty-eight (288) cases of OC including the major histological types were analyzed by immunohistochemistry for PD-L1HER2, ALK, and the mismatch repair (MMR) proteins MLH1, PMS2, MSH2, and MSH6. HER2 amplification and ALK/EML4 fusio...
Source: Virchows Archiv - Category: Pathology Source Type: research
Authors: Lopez S, Zeybek B, Santin AD PMID: 30613348 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
More News: Cancer & Oncology | Carcinoma | HER2 | Herceptin | OBGYN | Serous Carcinoma